Acellera

Acellera's mission is to transform drug discovery into a high-accuracy, computable task by developing algorithms that automate the process. Founded in 2016, the company has built a robust technology stack, including the QuantumBind® platform and open-source tools like ACEMD, OpenMM, and ACEGEN, backed by over 18 years of computational know-how and thousands of academic citations. While currently a private company with no external investment, Acellera is developing an internal pipeline of drug candidates and plans to raise funding in 2026 to scale its ambitious goals.

QuantumBind® is an integrated platform combining generative AI chemistry, neural network potentials trained on quantum mechanics data, and active learning to accelerate small-molecule discovery and potency optimization with quantum-level accuracy.

Acellera competes with AI-driven drug discovery companies like Exscientia, Recursion, and Schrödinger. Its differentiation stems from a strong foundation in physics-based simulation (ACEMD, OpenMM) and quantum chemistry, combined with AI, aiming for higher predictive accuracy. Its open-source contributions and dual platform/pipeline model also set it apart.